RIVA-CANDESARTAN TABLET
国家: 加拿大
语言: 英文
来源: Health Canada
产品特点
(SPC)
20-10-2016
该产品的某些文档当前不可用，您可以向我们的客户服务发送请求，我们将在获得它们后尽快通知您。
发送请求。
发送请求。
有效成分:
CANDESARTAN CILEXETIL
可用日期:
LABORATOIRE RIVA INC.
ATC代码:
C09CA06
INN（国际名称）:
CANDESARTAN
剂量:
32MG
药物剂型:
TABLET
组成:
CANDESARTAN CILEXETIL 32MG
给药途径:
ORAL
每包单位数:
30/100
处方类型:
Prescription
治疗领域:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
產品總結:
Active ingredient group (AIG) number: 0135220004; AHFS:
授权状态:
CANCELLED POST MARKET
授权日期:
2019-04-01
产品特点
_RIVA-CANDESARTAN Product Monograph_
_Page 1 of 38_
PRODUCT MONOGRAPH
PR
RIVA-CANDESARTAN
Candesartan cilexetil tablets
4 mg, 8 mg, 16 mg and 32 mg
ANGIOTENSIN II AT
1 RECEPTOR BLOCKER
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Québec
J7C 3V4
www.labriva.com
DATE OF REVISION
:
October 17, 2016
Submission Control No: 198061
_RIVA-CANDESARTAN Product Monograph_
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
..................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
16
OVERDOSAGE
................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 19
STORAGE AND STABILITY
.........................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 22
PART II: SCIENTIFIC INFORMATION
.............................................................................
23
PHARMACEUTICAL INFORMATION
.........................................................................
23
CLINICAL TRIALS
............................................................................................
阅读完整的文件
